2-[(4-phenyl-3,6-dihydropyridin-1(2H)-yl)methyl]-1H-benzimidazole | 159557-22-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-[(4-phenyl-3,6-dihydropyridin-1(2H)-yl)methyl]-1H-benzimidazole
• 英文别名: 2-(4-phenyl-1,2,3,6-tetrahydropyrid-1-ylmethyl)benzimidazole；2-[(4phenyl-3,6-dihydropyridin-1(2H)-yl)methyl]-1H-benzimidazole；2-(4-Phenyl-3,6-dihydro-2H-pyridin-1-ylmethyl)-1H-benzoimidazole；2-[(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)methyl]-1H-benzimidazole
• CAS: 159557-22-9
• 化学式: C₁₉H₁₉N₃
• 分子量: 289.38
• InChiKey: DZNZGCABZHIRPU-UHFFFAOYSA-N

物化性质

• 沸点：
  523.4±50.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  31.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,2,3,6-四氢-4-苯基吡啶盐酸盐 生成 2-[(4-phenyl-3,6-dihydropyridin-1(2H)-yl)methyl]-1H-benzimidazole
  参考文献：
  名称：

  Benzimidazoles that are useful in treating sexual dysfunction

  摘要：

  本发明涉及使用式（I）的化合物治疗性功能障碍，以及含有式（I）的化合物用于治疗性功能障碍的组合物，其中 L为C 1-4 烷基； R A ，R B ，R C ，R D 和R E 如规范中所述； Z选自N、C和CH组成的群；以及 A为规范中描述的芳基和杂环芳基。

  公开号：

  US06960589B2

文献信息

• [EN] BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION<br/>[FR] BENZIMIDAZOLES UTILES DANS LE TRAITEMENT DE TROUBLES SEXUELS
  申请人：ABBOTT LAB

  公开号：WO2002088093A1

  公开（公告）日：2002-11-07

  The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

  本发明涉及使用式(I)化合物治疗性功能障碍，以及含有式(I)化合物的组合物治疗性功能障碍。
• [EN] BENZIMIDAZOLE-DERIVATIVES FOR THE TREATMENT OF SEXUAL DYSFUNCTION<br/>[FR] DERIVES DE BENZIMIDAZOLE UTILISES POUR TRAITER UN DYSFONCTIONNEMENT SEXUEL
  申请人：ABBOTT LAB

  公开号：WO2003076431A1

  公开（公告）日：2003-09-18

  The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

  本发明涉及使用式(I)的化合物治疗性功能障碍，以及含有式(I)的化合物的组合物治疗性功能障碍。
• [EN] BENZIMIDAZOLE DERIVATIVES<br/>[FR] DERIVES BENZIMIDAZOLIQUES
  申请人：MERCK SHARP & DOHME LIMITED

  公开号：WO1994021615A1

  公开（公告）日：1994-09-29

  (EN) A class of chemical compounds comprising a benzimidazole moiety and a substituted heterocyclic moiety, linked via the 3-position of the benzimidazole moiety by a methylene group, are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia.(FR) Classe de composés chimiques comportant une fraction benzimidazolique et une fraction hétérocyclique substituée, liées en position 3 de la fraction benzimidazolique par un groupe méthylène. Ces composés sont des ligands pour les sous-types récepteurs de dopamine dans l'organisme. Par conséquent, ils sont utilisables dans le traitement et/ou la prophylaxie des troubles du système dopamine, notamment la schizophrénie.

  这类化学化合物包含一个苯并imidazole基团和一个取代杂环基团，通过苯并imidazole基团的3位用甲基烯基连接起来。它们作为体内 dopamine 受体亚型的配体。因此，它们在治疗和/或预防与 dopamine系统有关的疾病，尤其是精神分裂症中有潜在用途。
• Discovery of 2-(4-Pyridin-2-ylpiperazin-1-ylmethyl)-1<i>H</i>-benzimidazole (ABT-724), a Dopaminergic Agent with a Novel Mode of Action for the Potential Treatment of Erectile Dysfunction
  作者：Marlon Cowart、Steven P. Latshaw、Pramila Bhatia、Jerome F. Daanen、Jeffrey Rohde、Sherry L. Nelson、Meena Patel、Teodozyi Kolasa、Masaki Nakane、Marie E. Uchic、Loan N. Miller、Marc A. Terranova、Renjie Chang、Diana L. Donnelly-Roberts、Marian T. Namovic、Peter R. Hollingsworth、Brenda R. Martino、James J. Lynch、James P. Sullivan、Gin C. Hsieh、Robert B. Moreland、Jorge D. Brioni、Andrew O. Stewart

  DOI：10.1021/jm030505a

  日期：2004.7.1

  A new class of agents with potential utility for the treatment of erectile dysfunction has been discovered, guided by the hypothesis that selective D-4 agonists are erectogenic but devoid of the side effects typically associated with dopaminergic agents. The lead agent 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (1, ABT-724) was discovered by optimization of a series of benzimidazole arylpiperazines. This highly selective D-4 agonist was found to be very potent and efficacious in vivo, eliciting penile erections in rats at a dose of 0.03 mumol/kg, with a positive response rate of 77% erectile incidence. Even at high doses, it was devoid of side effects in animal models of central nervous system behaviors, emesis, or nausea. The structure-activity relationship of the parent benzimidazole series leading to 1 is described, with the detailed in vitro and in vivo profiles described. Distinctive structural features were discovered that are associated with D-4 selective agonism in this series of analogues.
• BENZIMIDAZOLE DERIVATIVES
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0689535A1

  公开（公告）日：1996-01-03